At a glance
ClinicalIndex Comparison RecordPhase 2Active· 50 enrolled
Drug / intervention
Ipilimumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
In Brief
A Phase 2 clinical trial evaluating Ipilimumab, Nivolumab, and 1 other intervention for Renal Cell Carcinoma. Active but no longer recruiting, targeting 50 participants across 3 sites.
Detailed Summary
To learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
2023202420252026
First PostedAug 2022
Enrollment StartFeb 2023
TodayJul 2026
Primary CompletionNov 2026
First PostedAug 15, 2022
Enrollment StartFeb 9, 2023
Primary CompletionNov 1, 2026
TodayJul 1, 2026
Enrollment to primary: 3.7 yearsPosted 3.9 years agoPrimary completion in 4 months
Interventions
Ipilimumabdrug
Given by IV (vein)
Nivolumabdrug
Given by IV (vein)
Ciforadenantdrug
Given by PO